Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811564 · ClinicalTrials.gov registry record · Phase 4
An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 148
- Enrollment target
NCT00811564: Completed Phase 4 study, sponsored by Allergan.
NCT00811564 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 148 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00811564, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 148 participants
- Enrollment target
Study Summary
A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects
Primary Outcome
Mean IOP at week 12. IOP is a measurement of the fluid pressure inside the eye.
Interventions
- DRUG fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
- DRUG latanoprost 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
What the finished NCT00811564 record still lists
NCT00811564 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution is the first listed.
NCT00811564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00811564 about?
NCT00811564 is a clinical study titled "An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects". A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects
What is the current status of trial NCT00811564?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 148 participants. The study started on 2008-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00811564?
The interventions under investigation include: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (DRUG), latanoprost 0.005% (DRUG).
Who is sponsoring clinical trial NCT00811564?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00811564's enrollment target sits among peer trials
148 567th of 2000 higher than 1,431 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia